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Viral infection induces a number of cytokines that shape T cell responses. In this issue of Immunity, Ray et al.
(2014) describe how CD4+ T cells decide on T follicular helper (Tfh) or T helper 1 (Th1) cell skewed gene
expression during acute viral infection.Follicular helper T (Tfh) cells are uniquely
specialized to provide B cell help. Under-
standing their differentiation program
will be the key for future vaccination
strategies and new therapeutic options
in autoimmune diseases like systemic
lupus erythematosus (SLE) or rheumatoid
arthritis (RA). However, we might not
be able to make use of or manipulate
the underlying program without study-
ing how Tfh cell differentiation and plas-
ticity connect to alternative programs
and how genetic and environmental im-
pacts select between these differentia-
tion programs in specific immunological
contexts.
CD4+ T cell differentiation starts with
antigen recognition by a naive T cell that
causes dramatic cellular changes in the
activation status, metabolism, and cell
cycle. CD4+ T cells can differentiate into
the T helper 1 (Th1), Th2, Th17, regulatory
T (Treg) or Tfh cell subsets characterized
by distinct gene-expression profiles.
These relate to the expression of a sub-
set-specifying transcription factor and
to specific effector functions due to the
ability to express hallmark cytokines. The
activity of the signaling molecules within
the differentiating T cell are placed in a
complex regulatory network in order to
create a differential gene-expression pro-
file that enables appropriate effector T cell
phenotypes. It integrates diverse signals
from the T cell receptor (TCR) and costi-
mulatory receptors as well as the humoral
context. Not surprisingly, the strength of
TCR stimulation and the input from spe-
cific cytokines have been determined
as major factors. Consistently, Tfh differ-
entiation depends on increased TCR
signal strength and is stimulated byinterleukin-6 (IL-6) and IL-21 cytokines
(Yamane and Paul, 2012). The Tfh cell
phenotype is characterized by expression
of the subset-determining transcription
factor Bcl6 and is associated with down-
regulated expression of its antagonistic
transcription factor Blimp-1. These cells
have the ability to produce IL-21 and are
localized in the B cell follicle as a result
of expression of the chemokine receptor
CXCR5. In addition, they are character-
ized by high expression of the costimula-
tory molecules PD-1, BTLA, and ICOS.
Signal transduction by IL-21 and IL-6
converge on the activation of STAT3
and STAT1 (Yamane and Paul, 2012).
However, the relative roles of STAT1
and STAT3 in Tfh cell induction during
acute viral infection have not been fully
understood.
Ray et al. now shed light on this issue
by analyzing the immune response
against lymphocytic choriomeningitis vi-
rus (LCMV) in mice with STAT3-deficient
T cells. Compared to wild-type (WT)
mice, they find that Tfh cell differentiation
was impaired 8 days after infection and
that both polyclonal and GP66-specific
Tfh cell numbers were decreased. This
reduction in Tfh cells led to defective
germinal center generation accompanied
by reduced production of LCMV-specific
antibodies. These findings greatly expand
the importance of STAT3 compared to
earlier results by Choi et al. (2013), who
suggested that STAT1 was required,
whereas STAT3 function only contributed
to Tfh cell differentiation in the early
phase of LCMV infection. However, those
results were obtained only with TCR-
transgenic T cells and did not include
analyses of germinal center B cell differ-Immunity 4entiation and antibody formation. Per-
forming a comprehensive gene-expres-
sion analysis, Ray et al. demonstrated
that STAT3-deficient Tfh cells expressed
less of the subset-specifying transcription
factor Bcl6, as well as hallmark cytokine
IL-21, and instead upregulated markers
of Th1 cell differentiation including CD25
and T-bet. The detailed comparison of
gene expression in Tfh cells from WT
or STAT3-deficient mice also revealed
that Cxcr5, Icos and IL6st were down-
regulated, whereas Prdm1, the gene that
encodes Blimp-1, the antagonist of Bcl6,
was highly increased. Most strikingly,
cluster analysis of different mRNA sam-
ples demonstrated that STAT3-deficient
Tfh cells appeared more closely related
to Th1 cells located in the T cell zone
(Ly6Clo, PSGL-1hi) than to Tfh cells from
WT mice. The lack of STAT3 was at
the same time associated with a higher
expression of interferon (IFN)-inducible
genes.
An earlier publication has generated
strong evidence for a connection of
IFN-g with the Tfh cell subset by investi-
gating the sanroque mice, which express
the posttranscriptional regulator Roquin-
1 only in its point-mutated (M199R) form.
Sanroque mice develop lupus-like dis-
ease due to accumulation of Tfh cells.
In fact, experimentally introduced defi-
ciency for the IFN-g receptor rescues
Tfh cell accumulation and Tfh cell-medi-
ated pathology in the sanroque mouse
strain (Lee et al., 2012). However, in the
present study by Ray et al. there was no
significant effect of IFN-g blockade on
Tfh cell differentiation in response to
acute viral infection. Together, these find-
ings rather suggest a role for IFN-g in Tfh0, March 20, 2014 ª2014 Elsevier Inc. 307
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Figure 1. Naive CD4+ T Cells Integrate TCR, Type I Interferon, IL-2, and IL-6 Signaling to
Decide on Tfh or Th1 Cell Differentiation
IL-6 signaling activates STAT3, which then binds and activates the Bcl6 promoter. Type I interferon
signaling induces IL-2 and CD25 expression, which in turn activate STAT5. The scheme also depicts
the implicated competitive replacement of STAT3 by STAT5 on the Bcl6 locus. In addition, STAT3 inhibits
the type I IFN–IL-2–CD25–STAT5 signaling pathway by a not-yet-defined molecular mechanism. Please
note that for simplicity reasons, this representation omits previously demonstrated regulatory mecha-
nisms, including the upregulation of Blimp1 by STAT5, the antagonism of Blimp1 and Bcl6, the induction
of T-bet by STAT1, and the regulation of Bcl6 binding to DNA by T-bet, which might act in concert.
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specific context of the sanroquemutation.
In the next step, Ray et al. tested
whether type I IFN would have an impact
on Tfh differentiation during viral infec-
tion. Indeed, blocking antibodies against
IFN-abR brought back the frequencies
of STAT3-deficient Tfh cells to WT and
could also rescue the germinal center
B cell and antibody responses. At the
same time, the lack of IFN-ab signaling
led to a strong reduction of Th1 cell
differentiation in WT, as well as in
STAT3-deficient T cells. Thus, one role
of STAT3 is to counteract the inhibitory
effects of type I IFN signaling during
Tfh cell differentiation in vivo. These
findings are in contrast to very recently
published data showing that addition
of type I interferon in cell culture ex-
periments was able to induce a Tfh-like
phenotype. However, these in vitro
differentiation conditions only induced
an incomplete phenotype, because they
did not bring about IL-21 production308 Immunity 40, March 20, 2014 ª2014 Elseand so far lack in vivo confirmation
(Nakayamada et al., 2014).
To describe the mechanism, Ray and
colleagues analyzed IFN-abR-deficient
T cells that are virus-specific due to
expression of a TCR transgene. After
adoptive transfer into WT mice, LCMV
infection yielded a higher percentage of
Tfh cells for IFN-abR-deficient compared
to WT TCR transgenic T cells. In vitro
studies with peptide stimulation of these
TCR-transgenic T cells provided addi-
tional important mechanistic insight.
In fact, the presence of IFN-b together
with IL-2 induced the expression of
CD25 and led to a drastic activation
of STAT5 (Figure 1). Importantly, chro-
matin immunoprecipitation experiments
showed that in this way STAT3, which
was bound to the Bcl6 locus after IL-6
stimulation, was replaced by STAT5
upon IFN-b stimulation. These findings
nicely connect to the observation that
deficiency of STAT3 correlated with
decreased protein amounts of Bcl6 andvier Inc.increased protein amounts of CD25 and
T-bet protein in Tfh cells. Therefore, type
I interferon signaling via the IL-2–CD25–
STAT5 axis inhibits Tfh cell differentiation
and modulates the immune response
toward a Th1 cell phenotype. STAT3 is
counteracting this pathway upstream by
inhibiting type I IFN-induced CD25
expression, as well as downstream by
competing with STAT5 for binding to
the Bcl6 locus (Figure 1). One key ques-
tion for future studies will be to find out
how the competitive binding to the same
cis-regulatory elements by STAT5 or
STAT3 actually translate into Bcl6 gene
repression or activation, respectively.
Another issue for future consideration is
which molecular targets of STAT3 can
explain its inhibitory effect on IL-2–CD25
signaling.
Type I interferon signaling has also
been involved in the reprogramming
of established Th2 cells to generate a
stable subset of ‘‘Th2+1’’ cells that mount
protective responses against viral infec-
tion. This has been demonstrated in ex-
periments involving adoptive transfer of
in vitro differentiated virus-specific Th2
cells into mice that are subsequently in-
fected with LCMV (Hegazy et al., 2010).
In this model, type I and type II interferons
are proposed to act as ‘‘door openers’’ to
enable STAT1–STAT4-mediated induc-
tion of T-bet in addition to a maintained
GATA3 expression. Interestingly, the
infection of mice with influenza virus
reveals similar plasticity from Tfh to Th1
cells, because Tfh cells established
during a primary infection lose Tfh cell
marker and effector molecule expression
and are converted toward a Th1 cell
phenotype following adoptive transfer
and secondary influenza infection of the
host mice (Lu¨thje et al., 2012). However,
the type I IFN-mediated skewing toward
the Th1 cell subset is likely to impact early
in the differentiation of CD4+ T cells. This
type of negative regulation by IL-2 and
STAT5 signaling has been well estab-
lished in Tfh cell differentiation (Johnston
et al., 2012; Nurieva et al., 2012; Oestreich
et al., 2012). Moreover, the CD25–STAT5
signaling is important in Th1 and Th2
differentiation and favors Th1 over Th17
cell differentiation (Yamane and Paul,
2012). Yet, the study by Ray et al. con-
nects the molecular aspects by showing
that not only increased stimulation by
IL-2, but also IFN-b signaling, indirectly
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Previewsimpinge on the Bcl6 locus where STAT5
can outcompete STAT3 on shared bind-
ing sites to repress Bcl6 transcription
(Figure 1). Rather than opening closed
doors in CD4+ T cell differentiation,
type I interferons’ interference in Tfh
deviates differentiation toward Th1 cells,
if STAT3-activating signals are missing.
Besides the known adjuvant effect of
type I interferon on non-T cells, the pre-
sent study demonstrates a crucial impor-
tance for balanced cytokine signals to
enable efficient Tfh cell differentiation in
vaccination strategies. At the same time,
it highlights the potential of STAT3 as a
target to treat autoimmune diseases that
involve Tfh cells.REFERENCES
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Immune activation as a result of the recognition of damage-associated molecular patterns needs to be
controlled. In this issue of Immunity, Neumann et al. (2014) demonstrates that Clec12a is a receptor for
dead cells through the recognition of uric acid crystals and contributes to the dampening of the responses.C-type lectin receptors (CLRs) are
pattern-recognition receptors (PRRs)
that recognize microbial pathogen-asso-
ciatedmolecular patterns (PAMPs), which
leads to the induction of host immune re-
sponses against many pathogens (Robin-
son et al., 2006). In addition to acting as
PRRs for PAMPs, some CLRs also func-
tion as receptors for damage-associated
molecular patterns (DAMPs), which are
exposed or released upon cell death by
noninfectious insults such as tissue injury,
ischemia, and infarction. For example,
Lox-1 and MGL-1 are CLRs known to
recognize dead cells and are likely to act
as phagocytic receptors for dead cells
(Robinson et al., 2006). Some CLRs
coupled with immunoreceptor tyrosine-
based activationmotif (ITAM) or hemITAM
(hemi-immunoreceptor tyrosine-based
activation motif), such as Mincle (Clec4e)
and DNGR-1 (Clec9a), have also beenshown to recognize dead cells (Sancho
et al., 2009; Yamasaki et al., 2008). These
CLRs sense nonhomeostatic cell death
and thereby induce inflammation or pro-
motion of antigen presentation. These
immune responses against ‘‘damaged
self’’ are thought to be beneficial to main-
tain homeostasis of the organisms. In
contrast, the ‘‘anti-self’’ responses should
be immediately terminated to prevent tis-
sue damage or autoimmunity caused by
prolonged halmful immune reaction
against self. To date, however, negative
regulatory CLRs for dead cells have never
been identified. Several CLRs possesses
immunoreceptor tyrosine-based inhibi-
tory motif (ITIM) within their own cyto-
plasmic tails. Upon receptor engagement,
tyrosine residues within ITIM are phos-
phorylated and thus provide docking sites
for cytosolic negative regulatory proteins
such as SHP-1, SHP-2, or SHIP. InT cells, ITIM-containing costimulatory
inhibitory receptors CTLA-4 and PD-1
play critical roles in terminating activatory
signals delivered through ITAM-contain-
ing T cell receptor (TCR) complexes in
order to prevent autoimmunity. Likewise,
it is possible that unknown inhibitory
CLR(s) contribute to the negative regula-
tion of immune responses against
damaged self.
Clec12a (also called myeloid inhibitory
C-type lectin-like receptor, MICL) was
originally described as an ITIM-containing
inhibitory CLR expressed by human gran-
ulocytes and monocytes (Marshall et al.,
2006). It was suggested that Clec12a rec-
ognizes some endogenous ligands as
soluble Clec12a could bind to single-cell
suspensions isolated from various murine
tissues (Pyz et al., 2008). In this issue of
Immunity, Neumann et al. (2014) identified
Clec12a as an inhibitory CLR for dead0, March 20, 2014 ª2014 Elsevier Inc. 309
